For 2022, 216 508 confirmed cases of chlamydia infection were reported in 27 EU/EEA countries, with a crude notification rate of 88 cases per 100 000 population.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
Lymphogranuloma venereum (LGV) is a systemic sexually transmitted infection (STI) caused by Chlamydia trachomatis serovars L1, L2, or L3. In 2021, 1 124 cases of LGV were reported by 23 EU/EEA Member States.
For 2021, 27 EU/EEA Member States reported 184 542 confirmed cases of chlamydia infection. The crude notification rate was 74 cases per 100 000 population.
In a series of reports released by ECDC, a concerning rise in sexually transmitted infections (STIs) across Europe has been revealed indicating troubling trends and significant public health implications.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).